Eur Rev Med Pharmacol Sci:MiR-146a调节创伤性股骨头坏死中骨髓基质细胞的成骨分化和增殖

2019-02-06 MedSci MedSci原创

本研究旨在探讨微核糖核酸(miR)-146a在创伤性股骨头坏死中成骨分化和骨髓基质细胞(BMSCs)增殖中的调控机制。手术治疗的股骨颈骨折患者分为坏死组和非坏死组。通过定量实时-聚合酶链反应(qRT-PCR)检测从这些患者分离的BMSCs中miR-146a的表达水平。探讨miR-146a与BMSCs在创伤性股骨头坏死中的临床相关性。检测miR-146a对创伤性股骨头坏死中骨髓间充质干细胞成骨分化和

本研究旨在探讨微核糖核酸(miR)-146a在创伤性股骨头坏死中成骨分化和骨髓基质细胞(BMSCs)增殖中的调控机制。

手术治疗的股骨颈骨折患者分为坏死组和非坏死组。通过定量实时-聚合酶链反应(qRT-PCR)检测从这些患者分离的BMSCs中miR-146a的表达水平。探讨miR-146a与BMSCs在创伤性股骨头坏死中的临床相关性。检测miR-146a对创伤性股骨头坏死中骨髓间充质干细胞成骨分化和增殖的调节作用。此外,通过细胞计数试剂盒-8(CCK-8)测定分析细胞增殖。通过茜素红染色检测钙在细胞表面上的沉积以评估成骨分化。通过qRT-PCR检测BMSCs中成骨分化的成骨特异性基因,碱性磷酸酶(ALP)和骨钙蛋白(Ocn)的信使RNA(mRNA)表达。

结果显示,坏死组骨髓间充质干细胞miR-146a表达水平明显低于非坏死组,差异有统计学意义(p <0.01)。CCK-8测定显示,与miR-NC组相比,miR-146a模拟组中BMSCs的增殖显著增强,而miR-146a抑制剂组中BMSCs的增殖明显低于miR-NC组。茜素红染色结果显示,与miR-NC组相相比,miR-146a模拟组钙的沉积明显增加,表明成骨分化能力显著增强,而miR-146a抑制剂显著降低。通过qRT-PCR检测成骨特异性基因表明,与miR-NC组相比,miR-146a模拟组中ALP和Ocn的mRNA表达显著增加,且差异有统计学意义(p <0.05)。miR-146a抑制剂组ALP和Ocn mRNA表达明显低于miR-NC组,差异有统计学意义(p <0.05),提示成骨分化能力受抑制。

总之,该研究结果表明,miR-146a可调节创伤性股骨头坏死中BMSCs的成骨分化和增殖。

原始出处:

Kong Y1, Chen ZT. MiR-146a regulates osteogenic differentiation and proliferation of bone marrow stromal cells in traumatic femoral head necrosis. Eur Rev Med Pharmacol Sci. 2019 Jan;23(2):441-448. doi: 10.26355/eurrev_201901_16853.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (17)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1996269, encodeId=d83e199626971, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Aug 02 00:38:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025487, encodeId=de19202548e10, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Mon May 13 17:38:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036289, encodeId=50af2036289a3, content=<a href='/topic/show?id=07f11183151' target=_blank style='color:#2F92EE;'>#miR-146a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11831, encryptionId=07f11183151, topicName=miR-146a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f1d390, createdName=feifers, createdTime=Tue Sep 17 12:38:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908518, encodeId=afeb190851802, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue May 14 21:38:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721859, encodeId=76ab1e218597a, content=<a href='/topic/show?id=01811016363e' target=_blank style='color:#2F92EE;'>#骨头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101636, encryptionId=01811016363e, topicName=骨头)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cd033099978, createdName=redcrab, createdTime=Sun Jun 02 10:38:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757156, encodeId=463f1e57156f8, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Tue Jul 16 12:38:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787583, encodeId=38581e8758366, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Dec 24 21:38:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1821391, encodeId=2ba81821391f8, content=<a href='/topic/show?id=428a101612e7' target=_blank style='color:#2F92EE;'>#骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101612, encryptionId=428a101612e7, topicName=骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Thu Oct 10 08:38:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788354, encodeId=6ef11e8835406, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Wed Mar 20 23:38:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930685, encodeId=9a1a1930685cf, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed May 22 01:38:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
    2019-08-02 yb6560
  2. [GetPortalCommentsPageByObjectIdResponse(id=1996269, encodeId=d83e199626971, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Aug 02 00:38:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025487, encodeId=de19202548e10, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Mon May 13 17:38:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036289, encodeId=50af2036289a3, content=<a href='/topic/show?id=07f11183151' target=_blank style='color:#2F92EE;'>#miR-146a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11831, encryptionId=07f11183151, topicName=miR-146a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f1d390, createdName=feifers, createdTime=Tue Sep 17 12:38:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908518, encodeId=afeb190851802, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue May 14 21:38:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721859, encodeId=76ab1e218597a, content=<a href='/topic/show?id=01811016363e' target=_blank style='color:#2F92EE;'>#骨头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101636, encryptionId=01811016363e, topicName=骨头)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cd033099978, createdName=redcrab, createdTime=Sun Jun 02 10:38:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757156, encodeId=463f1e57156f8, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Tue Jul 16 12:38:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787583, encodeId=38581e8758366, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Dec 24 21:38:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1821391, encodeId=2ba81821391f8, content=<a href='/topic/show?id=428a101612e7' target=_blank style='color:#2F92EE;'>#骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101612, encryptionId=428a101612e7, topicName=骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Thu Oct 10 08:38:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788354, encodeId=6ef11e8835406, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Wed Mar 20 23:38:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930685, encodeId=9a1a1930685cf, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed May 22 01:38:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
    2019-05-13 amyloid
  3. [GetPortalCommentsPageByObjectIdResponse(id=1996269, encodeId=d83e199626971, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Aug 02 00:38:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025487, encodeId=de19202548e10, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Mon May 13 17:38:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036289, encodeId=50af2036289a3, content=<a href='/topic/show?id=07f11183151' target=_blank style='color:#2F92EE;'>#miR-146a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11831, encryptionId=07f11183151, topicName=miR-146a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f1d390, createdName=feifers, createdTime=Tue Sep 17 12:38:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908518, encodeId=afeb190851802, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue May 14 21:38:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721859, encodeId=76ab1e218597a, content=<a href='/topic/show?id=01811016363e' target=_blank style='color:#2F92EE;'>#骨头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101636, encryptionId=01811016363e, topicName=骨头)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cd033099978, createdName=redcrab, createdTime=Sun Jun 02 10:38:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757156, encodeId=463f1e57156f8, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Tue Jul 16 12:38:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787583, encodeId=38581e8758366, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Dec 24 21:38:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1821391, encodeId=2ba81821391f8, content=<a href='/topic/show?id=428a101612e7' target=_blank style='color:#2F92EE;'>#骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101612, encryptionId=428a101612e7, topicName=骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Thu Oct 10 08:38:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788354, encodeId=6ef11e8835406, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Wed Mar 20 23:38:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930685, encodeId=9a1a1930685cf, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed May 22 01:38:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
    2019-09-17 feifers
  4. [GetPortalCommentsPageByObjectIdResponse(id=1996269, encodeId=d83e199626971, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Aug 02 00:38:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025487, encodeId=de19202548e10, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Mon May 13 17:38:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036289, encodeId=50af2036289a3, content=<a href='/topic/show?id=07f11183151' target=_blank style='color:#2F92EE;'>#miR-146a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11831, encryptionId=07f11183151, topicName=miR-146a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f1d390, createdName=feifers, createdTime=Tue Sep 17 12:38:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908518, encodeId=afeb190851802, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue May 14 21:38:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721859, encodeId=76ab1e218597a, content=<a href='/topic/show?id=01811016363e' target=_blank style='color:#2F92EE;'>#骨头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101636, encryptionId=01811016363e, topicName=骨头)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cd033099978, createdName=redcrab, createdTime=Sun Jun 02 10:38:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757156, encodeId=463f1e57156f8, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Tue Jul 16 12:38:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787583, encodeId=38581e8758366, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Dec 24 21:38:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1821391, encodeId=2ba81821391f8, content=<a href='/topic/show?id=428a101612e7' target=_blank style='color:#2F92EE;'>#骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101612, encryptionId=428a101612e7, topicName=骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Thu Oct 10 08:38:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788354, encodeId=6ef11e8835406, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Wed Mar 20 23:38:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930685, encodeId=9a1a1930685cf, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed May 22 01:38:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1996269, encodeId=d83e199626971, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Aug 02 00:38:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025487, encodeId=de19202548e10, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Mon May 13 17:38:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036289, encodeId=50af2036289a3, content=<a href='/topic/show?id=07f11183151' target=_blank style='color:#2F92EE;'>#miR-146a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11831, encryptionId=07f11183151, topicName=miR-146a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f1d390, createdName=feifers, createdTime=Tue Sep 17 12:38:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908518, encodeId=afeb190851802, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue May 14 21:38:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721859, encodeId=76ab1e218597a, content=<a href='/topic/show?id=01811016363e' target=_blank style='color:#2F92EE;'>#骨头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101636, encryptionId=01811016363e, topicName=骨头)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cd033099978, createdName=redcrab, createdTime=Sun Jun 02 10:38:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757156, encodeId=463f1e57156f8, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Tue Jul 16 12:38:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787583, encodeId=38581e8758366, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Dec 24 21:38:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1821391, encodeId=2ba81821391f8, content=<a href='/topic/show?id=428a101612e7' target=_blank style='color:#2F92EE;'>#骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101612, encryptionId=428a101612e7, topicName=骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Thu Oct 10 08:38:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788354, encodeId=6ef11e8835406, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Wed Mar 20 23:38:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930685, encodeId=9a1a1930685cf, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed May 22 01:38:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
    2019-06-02 redcrab
  6. [GetPortalCommentsPageByObjectIdResponse(id=1996269, encodeId=d83e199626971, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Aug 02 00:38:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025487, encodeId=de19202548e10, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Mon May 13 17:38:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036289, encodeId=50af2036289a3, content=<a href='/topic/show?id=07f11183151' target=_blank style='color:#2F92EE;'>#miR-146a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11831, encryptionId=07f11183151, topicName=miR-146a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f1d390, createdName=feifers, createdTime=Tue Sep 17 12:38:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908518, encodeId=afeb190851802, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue May 14 21:38:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721859, encodeId=76ab1e218597a, content=<a href='/topic/show?id=01811016363e' target=_blank style='color:#2F92EE;'>#骨头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101636, encryptionId=01811016363e, topicName=骨头)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cd033099978, createdName=redcrab, createdTime=Sun Jun 02 10:38:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757156, encodeId=463f1e57156f8, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Tue Jul 16 12:38:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787583, encodeId=38581e8758366, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Dec 24 21:38:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1821391, encodeId=2ba81821391f8, content=<a href='/topic/show?id=428a101612e7' target=_blank style='color:#2F92EE;'>#骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101612, encryptionId=428a101612e7, topicName=骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Thu Oct 10 08:38:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788354, encodeId=6ef11e8835406, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Wed Mar 20 23:38:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930685, encodeId=9a1a1930685cf, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed May 22 01:38:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1996269, encodeId=d83e199626971, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Aug 02 00:38:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025487, encodeId=de19202548e10, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Mon May 13 17:38:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036289, encodeId=50af2036289a3, content=<a href='/topic/show?id=07f11183151' target=_blank style='color:#2F92EE;'>#miR-146a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11831, encryptionId=07f11183151, topicName=miR-146a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f1d390, createdName=feifers, createdTime=Tue Sep 17 12:38:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908518, encodeId=afeb190851802, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue May 14 21:38:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721859, encodeId=76ab1e218597a, content=<a href='/topic/show?id=01811016363e' target=_blank style='color:#2F92EE;'>#骨头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101636, encryptionId=01811016363e, topicName=骨头)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cd033099978, createdName=redcrab, createdTime=Sun Jun 02 10:38:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757156, encodeId=463f1e57156f8, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Tue Jul 16 12:38:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787583, encodeId=38581e8758366, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Dec 24 21:38:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1821391, encodeId=2ba81821391f8, content=<a href='/topic/show?id=428a101612e7' target=_blank style='color:#2F92EE;'>#骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101612, encryptionId=428a101612e7, topicName=骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Thu Oct 10 08:38:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788354, encodeId=6ef11e8835406, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Wed Mar 20 23:38:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930685, encodeId=9a1a1930685cf, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed May 22 01:38:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
    2019-12-24 jj000001
  8. [GetPortalCommentsPageByObjectIdResponse(id=1996269, encodeId=d83e199626971, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Aug 02 00:38:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025487, encodeId=de19202548e10, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Mon May 13 17:38:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036289, encodeId=50af2036289a3, content=<a href='/topic/show?id=07f11183151' target=_blank style='color:#2F92EE;'>#miR-146a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11831, encryptionId=07f11183151, topicName=miR-146a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f1d390, createdName=feifers, createdTime=Tue Sep 17 12:38:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908518, encodeId=afeb190851802, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue May 14 21:38:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721859, encodeId=76ab1e218597a, content=<a href='/topic/show?id=01811016363e' target=_blank style='color:#2F92EE;'>#骨头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101636, encryptionId=01811016363e, topicName=骨头)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cd033099978, createdName=redcrab, createdTime=Sun Jun 02 10:38:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757156, encodeId=463f1e57156f8, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Tue Jul 16 12:38:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787583, encodeId=38581e8758366, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Dec 24 21:38:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1821391, encodeId=2ba81821391f8, content=<a href='/topic/show?id=428a101612e7' target=_blank style='color:#2F92EE;'>#骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101612, encryptionId=428a101612e7, topicName=骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Thu Oct 10 08:38:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788354, encodeId=6ef11e8835406, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Wed Mar 20 23:38:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930685, encodeId=9a1a1930685cf, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed May 22 01:38:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
    2019-10-10 HinsMax
  9. [GetPortalCommentsPageByObjectIdResponse(id=1996269, encodeId=d83e199626971, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Aug 02 00:38:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025487, encodeId=de19202548e10, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Mon May 13 17:38:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036289, encodeId=50af2036289a3, content=<a href='/topic/show?id=07f11183151' target=_blank style='color:#2F92EE;'>#miR-146a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11831, encryptionId=07f11183151, topicName=miR-146a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f1d390, createdName=feifers, createdTime=Tue Sep 17 12:38:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908518, encodeId=afeb190851802, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue May 14 21:38:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721859, encodeId=76ab1e218597a, content=<a href='/topic/show?id=01811016363e' target=_blank style='color:#2F92EE;'>#骨头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101636, encryptionId=01811016363e, topicName=骨头)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cd033099978, createdName=redcrab, createdTime=Sun Jun 02 10:38:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757156, encodeId=463f1e57156f8, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Tue Jul 16 12:38:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787583, encodeId=38581e8758366, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Dec 24 21:38:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1821391, encodeId=2ba81821391f8, content=<a href='/topic/show?id=428a101612e7' target=_blank style='color:#2F92EE;'>#骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101612, encryptionId=428a101612e7, topicName=骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Thu Oct 10 08:38:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788354, encodeId=6ef11e8835406, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Wed Mar 20 23:38:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930685, encodeId=9a1a1930685cf, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed May 22 01:38:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1996269, encodeId=d83e199626971, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Aug 02 00:38:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025487, encodeId=de19202548e10, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Mon May 13 17:38:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036289, encodeId=50af2036289a3, content=<a href='/topic/show?id=07f11183151' target=_blank style='color:#2F92EE;'>#miR-146a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11831, encryptionId=07f11183151, topicName=miR-146a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f1d390, createdName=feifers, createdTime=Tue Sep 17 12:38:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908518, encodeId=afeb190851802, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue May 14 21:38:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721859, encodeId=76ab1e218597a, content=<a href='/topic/show?id=01811016363e' target=_blank style='color:#2F92EE;'>#骨头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101636, encryptionId=01811016363e, topicName=骨头)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cd033099978, createdName=redcrab, createdTime=Sun Jun 02 10:38:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757156, encodeId=463f1e57156f8, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Tue Jul 16 12:38:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787583, encodeId=38581e8758366, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Dec 24 21:38:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1821391, encodeId=2ba81821391f8, content=<a href='/topic/show?id=428a101612e7' target=_blank style='color:#2F92EE;'>#骨分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101612, encryptionId=428a101612e7, topicName=骨分化)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Thu Oct 10 08:38:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788354, encodeId=6ef11e8835406, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Wed Mar 20 23:38:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930685, encodeId=9a1a1930685cf, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed May 22 01:38:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
    2019-05-22 smallant2002